NCT05170113已完成不适用
A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Effectiveness and Safety of an Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health Among Overall Healthy Participants
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 79
- 试验地点
- 2
- 主要终点
- VAS-F (Visual Analogue Scale to Evaluate Fatigue Severity)
研究概览
简要总结
The purpose of this study is to assess the effectiveness and safety of the Alpinia galanga formulation, Theacrine formulation, and Caffeine formulation on fatigue, mental acuity, and cognitive health among overall healthy participants
详细描述
This is a 4-arm pilot, double-blind, randomized, placebo-controlled, parallel design study. A total of 80 subjects (20 per treatment arm) will be enrolled in a randomly assigned sequence to receive either the Alpinia galanga formulation, Theacrine formulation, Caffeine formulation, or placebo in individuals and admit to experiencing occasional fatigue (tiredness) and would like more energy.
Participants will need to complete assessments and questionnaires.
The primary objective is the evaluation of the change in the response to the VAS-F (Visual Analogue Scale to Evaluate Fatigue Severity) relative to baseline. The secondary objective is the evaluation of the change in the responses to the BCAT-SF (Brief Cognitive Health Assessment Short Form), LSEQ (Leeds Sleep Evaluation Questionnaires), and SF-36 Health Survey (Short Form 36) compared to baseline.
Safety and tolerability will be evaluated through the receipt of documentation and responses from the telephone contacts/ emails per protocol.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Health Services Research
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ambulatory, male or female, 30-70 years of age
- •A body mass index (BMI) of 18.5 - 34.9
- •Admits to experiencing occasional fatigue (tiredness) and would like more energy
- •Has consumed no more than two cups of coffee or caffeinated beverage per day for seven or more days before Screening/baseline
- •Has personal access to and able to operate a smartphone, tablet, or computer with enough memory to accommodate additional application(s) and reliable internet service
- •Able to complete tests online with a computer
- •Able to print out and return documents by scan, email, or mail
- •Has regular daytime work hours or shifts, if employed (regular shift excludes night shift workers and those with rotating shifts)
- •Generally healthy and having no significant difficulty with digestion or absorption of food
- •Able to complete an Activity Log and Study Product Log daily
- •Has been generally weight stable for the past six months (give or take 6 lbs.)
- •Willing and able to give written informed consent
- •Clearly understands the procedures and study requirements
- •Willing and able to comply with all study procedures, as per protocol
- •Able to communicate, including reading, in English
- •Has not taken any nutritional supplements that may contain any of the components of the study products including Alpinia galanga, Theacrine or Caffeine for a minimum of 14 days before Screening/baseline
排除标准
- •Not having the basic skills needed to operate a smartphone, tablet, or computer
- •Unwilling to abstain from consuming more than two cups of coffee or caffeinated beverage/food per day and no caffeinated beverage/food after 10 am daily for the duration of the study
- •Having smoked any cigarette, electronic cigarette, cigar, or pipe, or used marijuana, any recreational drug or cannabidiol (CBD) in the past 30 days
- •Donated blood within the 30 days prior to Screening/baseline
- •Having participated in another study within 30 days before Screening/baseline
- •Being pregnant or planning on becoming pregnant during study participation; or breast feeding
- •History of allergy or sensitivity to any component of the study products
- •Currently taking or having taken within the 30 days prior to Screening/baseline any medication(s) or supplement(s) which may have a stimulant effect in the judgment of the Study Investigator/Sub-investigator
- •Having been diagnosed, received medical treatment, or taking medication daily for any of the following medical condition(s):
- •Chronic fatigue syndrome
- •Fibromyalgia
- •Sleep disorder, including sleep apnea
- •Presence of active or recurring clinically significant conditions as follows:
- •Diabetes mellitus or other endocrine disease
- •Eating disorder
- •Acute or chronic inflammatory disease or autoimmune disease
- •Cardiovascular disease including heart and blood vessel disease, arrhythmia, heart attack, stroke, or heart valve problem
- •Having a history of an abnormal electrocardiogram (ECG) unless permitted to proceed in the judgment of the Study Investigator/Sub-Investigator(s)
- •Gastrointestinal disease including gallbladder problems, gallstones, or biliary tract obstruction
- •Thyroid disease (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study)
- •Hypertension (unless on a stable dose of medication for 3 months before Screening/baseline and unlikely to change medication or dose during the study)
- •Neurologic condition/disease
- •Cancer (unless skin cancer other than melanoma which has been treated > 3 years before Screening/baseline)
- •Liver, pancreatic, and kidney disease
- •Pulmonary disease
- •Blood coagulation disorder or other hematologic disease
- •Other condition or medication use that would preclude participation in the study in the judgment of the Study Investigator/Sub-Investigator
- •Currently taking any medications or treatment for a psychiatric disorder (bipolar disorder, manic disorder, schizophrenia, apathetic [inherited] disorder), including antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs), tricyclic and atypical antidepressants, benzodiazepines, CNS depressants, dextromethorphan, meperidine, monoamine oxidase inhibitors (MAOIs), pentazocine, phenothiazines, and tramadol. These may preclude participation in the study depending on the judgment of the Study Investigator/Sub-Investigator
- •Currently taking or having taken within the 30 days before Screening/baseline any hormone replacement therapy (including DHEA, estrogen, progesterone, or testosterone; except those utilized as a method of birth control and which have been taken for > 3 months, with no anticipated change for the duration of the study). This may preclude participation in the study depending on the judgment of the Study Investigator/Sub-Investigator
- •Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-Investigator, would preclude participation in the study
- •Currently consumes more than 7 standard alcoholic drinks per week for women and 14 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)
- •Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges, and tangelos for the study period
- •History of known or suspected substance abuse (e.g., alcohol, opiates, Benzodiazepines, or amphetamines)
- •Having any other circumstance that precludes study participation in the judgment of the Study Investigator/Sub-Investigator including use of other nutritional supplements, which will be evaluated on a case-by-case basis
结局指标
主要结局
VAS-F (Visual Analogue Scale to Evaluate Fatigue Severity)
时间窗: 14 Days
Assessment of the mean change in the results of the VAS-F survey from baseline. This consists of 18 items relating to the subjective experience of fatigue with a Fatigue subscale and Energy subscale. The scores can range from 0-10 and the lower the score indicates a better outcome.
次要结局
- BCAT-SF (Brief Cognitive Health Assessment Short Form)(14 Days)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study Of Galcanezumab In Participants With Episodic Cluster HeadacheEpisodic Cluster HeadacheNCT02397473Eli Lilly and Company109
已完成
3 期
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 StudyMigraineNCT02614196Eli Lilly and Company986
已完成
2 期
Gilenya in Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisNCT01786174Massachusetts General Hospital30
已完成
3 期
Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With PioglitazoneDiabetes Mellitus, Type 2NCT00996658Boehringer Ingelheim278
已完成
3 期
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentAlzheimer DiseaseDementiaNCT00236431Johnson & Johnson Pharmaceutical Research & Development, L.L.C.1,063